MEDICAL COLLEGE OF WISCONSIN
The study’s findings suggest targeting protein FXR1 to inhibit the progression of the cMYC oncogene, a gene mutation often over-expressed in patients with ovarian cancer
Scientists at the Medical College of Wisconsin (MCW) Cancer Center and … Read more
By Krista Conger
It’s diabolical, and so clever. Recent research by cancer biologist Wendy Fantl, PhD, and immunologist and cancer biologist Veronica Gonzalez, PhD, shows that ovarian tumors thrive by convincing nearby immune cells that the cancer cells are those … Read more
By Krista Conger
Newly diagnosed breast or ovarian cancer patients who carry common cancer-associated mutations have similar or better short-term survival rates than those with no mutations, researchers report.
Women newly diagnosed with breast or ovarian cancer who are also … Read more
By Mike Bassett
— For those on active therapy, 80% had increased antibody levels, study showed
A third dose of Pfizer’s COVID-19 vaccine (BNT162b2; Comirnaty) could offer increased protection for cancer patients on active treatment, a new study suggested, as … Read more
By Jamie Cesanek
Maintenance therapy is meant to prevent relapse after a patient with ovarian cancer received their main treatment. Here’s an overview of what patients should know.
When a patient is diagnosed with ovarian cancer, their initial treatment typically
By Aatif Sulleyman
A woman is raising awareness of ovarian cancer and how difficult it can be to detect, having been diagnosed with the illness by a dermatologist who removed a small growth from her navel.
Despite being aware of … Read more
By Wistar Institute
Newswise — PHILADELPHIA — (Sept. 21, 2021) — Mutations in the ARID1A gene are present in more than 50% of ovarian clear cell carcinomas (OCCC), for which effective treatments are lacking. Scientists at The Wistar Institute discovered … Read more
By R. Colon-Thillet
Treatment for ovarian cancer across subtypes typically consists of platinum-based chemotherapies. However, this standard therapy is less effective against ovarian clear cell carcinoma (OCCC), a rare subtype of ovarian cancer with distinct pathology and genetic drivers. Advanced … Read more
The FDA has granted priority review to the new drug application for the novel compound pafolacianine sodium injection for use in the identification of ovarian cancer during surgery.
By Courtney Marabella
The FDA has granted priority review to the new
By Christina Bennett, MS
The number of genes tested for ovarian and breast cancer has grown in recent years, but most patients do not undergo testing. Thus, variant-of-unknown-significance (VUS) results are common, especially among minority populations, according to the results … Read more
Eleven years ago, my wife and I had the rug pulled out from under us. Michelle was diagnosed with ovarian cancer, and we were thrust into a new, alien world—Michelle as patient, and me as caregiver—a role I frankly wasn’t … Read more
